Evaluation of Mortality During Long-Term Treatment with Tafamidis for Transthyretin Amyloidosis with Polyneuropathy: Clinical Trial Results up to 8.5 Years
Crossref DOI link: https://doi.org/10.1007/s40120-020-00180-w
Published Online: 2020-02-27
Published Print: 2020-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Merlini, Giampaolo
Coelho, Teresa
Waddington Cruz, Márcia
Li, Huihua
Stewart, Michelle
Ebede, Ben
Funding for this research was provided by:
Pfizer Inc
FoldRx
Text and Data Mining valid from 2020-02-27
Version of Record valid from 2020-02-27
Article History
Received: 4 November 2019
First Online: 27 February 2020